Hubbry Logo
XanthineXanthineMain
Open search
Xanthine
Community hub
Xanthine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Xanthine
Xanthine
Xanthine
View on Wikipedia
from Wikipedia
Xanthine[1]
Names
Preferred IUPAC name
3,7-Dihydro-1H-purine-2,6-dione
Other names
1H-Purine-2,6-dione
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.000.653 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11) checkY
    Key: LRFVTYWOQMYALW-UHFFFAOYSA-N ☒N
  • InChI=1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)
  • InChI=1S/C5H4N4O2/c10-4-2-3(7-1-6-2)8-5(11)9-4/h1H,(H3,6,7,8,9,10,11)
    Key: LRFVTYWOQMYALW-UHFFFAOYSA-N
  • c1[nH]c2c(n1)nc(nc2O)O
Properties
C5H4N4O2
Molar mass 152.11 g/mol
Appearance White solid
Melting point decomposes
1 g/ 14.5 L @ 16 °C
1 g/1.4 L @ 100 °C
Hazards
NFPA 704 (fire diamond)
NFPA 704 four-colored diamondHealth 2: Intense or continued but not chronic exposure could cause temporary incapacitation or possible residual injury. E.g. chloroformFlammability 1: Must be pre-heated before ignition can occur. Flash point over 93 °C (200 °F). E.g. canola oilInstability 0: Normally stable, even under fire exposure conditions, and is not reactive with water. E.g. liquid nitrogenSpecial hazards (white): no code
2
1
0
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Xanthine (/ˈzænθiːn/ or /ˈzænθaɪn/, from Ancient Greek ξανθός xanthós 'yellow' for its yellowish-white appearance; archaically xanthic acid; systematic name 3,7-dihydropurine-2,6-dione) is a purine base found in most human body tissues and fluids, as well as in other organisms.[2] Several stimulants are derived from xanthine, including caffeine, theophylline, and theobromine.[3][4]

Xanthine is a product on the pathway of purine degradation.[2]

Xanthine is subsequently converted to uric acid by the action of the xanthine oxidase enzyme.[2]

Use and production

[edit]

Xanthine is used as a drug precursor for human and animal medications, and is produced as a pesticide ingredient.[2]

Clinical significance

[edit]

Derivatives of xanthine (known collectively as xanthines) are a group of alkaloids commonly used for their effects as mild stimulants and as bronchodilators, notably in the treatment of asthma or influenza symptoms.[2] In contrast to other, more potent stimulants like sympathomimetic amines, xanthines mainly act to oppose the actions of adenosine, and increase alertness in the central nervous system.[2]

Toxicity

[edit]

Methylxanthines (methylated xanthines), which include caffeine, aminophylline, IBMX, paraxanthine, pentoxifylline, theobromine, theophylline, and 7-methylxanthine (heteroxanthine), among others, affect the airways, increase heart rate and force of contraction, and at high concentrations can cause cardiac arrhythmias.[2] In high doses, they can lead to convulsions that are resistant to anticonvulsants.[2] Methylxanthines induce gastric acid and pepsin secretions in the gastrointestinal tract.[2] Methylxanthines are metabolized by cytochrome P450 in the liver.[2]

If swallowed, inhaled, or exposed to the eyes in high amounts, xanthines can be harmful, and they may cause an allergic reaction if applied topically.[2]

Pharmacology

[edit]
Xanthine: R1 = R2 = R3 = H
Caffeine: R1 = R2 = R3 = CH3
Theobromine: R1 = H, R2 = R3 = CH3
Theophylline: R1 = R2 = CH3, R3 = H

In in vitro pharmacological studies, xanthines act as both competitive nonselective phosphodiesterase inhibitors and nonselective adenosine receptor antagonists. Phosphodiesterase inhibitors raise intracellular cAMP, activate PKA, inhibit TNF-α synthesis,[2][5][4] and leukotriene[6] and reduce inflammation and innate immunity.[6] Adenosine receptor antagonists[7] inhibit sleepiness-inducing adenosine.[2]

However, different analogues show varying potency at the numerous subtypes, and a wide range of synthetic xanthines (some nonmethylated) have been developed searching for compounds with greater selectivity for phosphodiesterase enzyme or adenosine receptor subtypes.[2][8][7][9][10][11]

Examples of xanthine derivatives
Name R1 R2 R3 R8 IUPAC nomenclature Found in
Xanthine H H H H 3,7-Dihydro-purine-2,6-dione Plants, animals
7-Methylxanthine H H CH3 H 7-methyl-3H-purine-2,6-dione Metabolite of caffeine and theobromine
Theobromine H CH3 CH3 H 3,7-Dihydro-3,7-dimethyl-1H-purine-2,6-dione Cacao (chocolate), yerba mate, kola, guayusa
Theophylline CH3 CH3 H H 1,3-Dimethyl-7H-purine-2,6-dione Tea, cacao (chocolate), yerba mate, kola
Paraxanthine CH3 H CH3 H 1,7-Dimethyl-7H-purine-2,6-dione Animals that have consumed caffeine
Caffeine CH3 CH3 CH3 H 1,3,7-Trimethyl-1H-purine-2,6(3H,7H)-dione Coffee, guarana, yerba mate, tea, kola, guayusa, Cacao (chocolate)
8-Chlorotheophylline CH3 CH3 H Cl 8-Chloro-1,3-dimethyl-7H-purine-2,6-dione Synthetic pharmaceutical ingredient
8-Bromotheophylline CH3 CH3 H Br 8-Bromo-1,3-dimethyl-7H-purine-2,6-dione Pamabrom diuretic medication
Diprophylline CH3 CH3 C3H7O2 H 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione Synthetic pharmaceutical ingredient
IBMX CH3 C4H9 H H 1-Methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
Uric acid H H H O 7,9-Dihydro-1H-purine-2,6,8(3H)-trione Byproduct of purine nucleotides metabolism and a normal component of urine

Pathology

[edit]

People with rare genetic disorders, specifically xanthinuria and Lesch–Nyhan syndrome, lack sufficient xanthine oxidase and cannot convert xanthine to uric acid.[2]

Possible formation in absence of life

[edit]

Studies reported in 2008, based on 12C/13C isotopic ratios of organic compounds found in the Murchison meteorite, suggested that xanthine and related chemicals, including the RNA component uracil, have been formed extraterrestrially.[12][13] In August 2011, a report, based on NASA studies with meteorites found on Earth, was published suggesting xanthine and related organic molecules, including the DNA and RNA components adenine and guanine, were found in outer space.[14][15][16]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Xanthine

View on Grokipedia
from Grokipedia
Xanthine is a base with the molecular formula C₅H₄N₄O₂ and the IUPAC name 3,7-dihydropurine-2,6-dione. It occurs naturally in most tissues and fluids, certain , and some urinary calculi, serving as a key intermediate in the degradation of purine nucleotides such as to , the primary end product of in humans. In , xanthine is generated through the oxidation of hypoxanthine by the xanthine dehydrogenase (XDH) or (XO), and it is then further oxidized to by the same complex. This pathway is essential for the breakdown of nucleic acids from dietary sources and cellular turnover, with xanthine representing a critical step before the formation of , which is excreted primarily by the s. Disruptions in this process, such as deficiencies in XDH/XO due to genetic mutations, result in hereditary xanthinuria, a rare disorder characterized by elevated xanthine levels, , and the potential formation of poorly soluble xanthine crystals leading to kidney stones that can impair renal function. Xanthine is the parent structure for several biologically active methylated derivatives, collectively known as methylxanthines, including (1,3,7-trimethylxanthine), (3,7-dimethylxanthine), and (1,3-dimethylxanthine), which are abundant in common beverages such as , , cocoa, and . These compounds exert pharmacological effects by inhibiting enzymes, antagonizing receptors, and mobilizing intracellular calcium, leading to applications as bronchodilators in treatment, central nervous system stimulants, diuretics, and myocardial stimulants. Xanthine itself has limited direct clinical use but is employed in combination with to support liver function in cases of uncomplicated hepatic dysfunction.

Chemical Characteristics

Molecular Structure

Xanthine is a purine base with the molecular formula C₅H₄N₄O₂ and a molecular weight of 152.11 g/mol. As a derivative of , it features a bicyclic ring system composed of a fused and ring, where the six-membered ring shares two carbon atoms with the five-membered ring. The structure includes atoms at positions 1, 3, 7, and 9, along with keto (oxo) groups at carbons 2 and 6, resulting in a planar, aromatic system that contributes to its role in nucleic acid-related biochemistry. In its predominant tautomeric form, known as 9H-xanthine, the molecule adopts the oxo configuration with carbonyl groups at C2 and C6 and a proton at N9, which is the most stable isomer under physiological conditions. Alternative tautomers, such as the 7H-xanthine form or hydroxy variants where one or both oxo groups shift to hydroxyl groups (e.g., at C2 or C6), exist but are less prevalent due to higher energy states, as determined by theoretical studies on tautomerism. This preference for the oxo tautomer influences xanthine's hydrogen-bonding capabilities and interactions in biological contexts. Compared to other purines, xanthine distinguishes itself by the presence of two oxo groups without additional substituents; for instance, it lacks the amino group at C2 found in (2-amino-6-oxopurine), making xanthine a simpler 2,6-dioxopurine. Similarly, hypoxanthine is the monoxo analog with only a 6-oxo group and no substituent at C2, highlighting xanthine's additional oxidation state in the purine degradation pathway. These structural differences affect their reactivity and metabolic interconversions. The molecular structure of xanthine can be represented using SMILES notation as O=c1[nH]c2nc[nH]c2c(=O)[nH]1, which depicts the keto tautomer with explicit hydrogen placements on the nitrogens. This notation underscores the ring's and the positioning of functional groups essential for its chemical identity.

Physical and Chemical Properties

Xanthine is a crystalline powder that is odorless and tasteless. It exhibits low solubility in water, approximately 70 mg/L at 20 °C under neutral conditions, rendering it sparingly soluble at ; solubility increases markedly in hot water to about 710 mg/L at 100 °C, and it dissolves more readily in alkaline or acidic solutions due to or effects, while being slightly soluble in . The compound has a high exceeding 300 °C, at which it decomposes rather than melting. Xanthine displays amphoteric , with acidic properties arising from the N3-H and N7-H protons (pKa values of 7.44 and 11.12, respectively) and weak basicity attributed to its atoms (pKa ≈ -0.7). In , xanthine shows absorption maxima at approximately 206 nm and 260 nm in , characteristic of its ring system. Infrared spectroscopy reveals characteristic carbonyl stretching bands around 1700 cm⁻¹ and 1660 cm⁻¹, corresponding to the C2=O and C6=O groups, respectively. Xanthine demonstrates thermal stability up to its decomposition temperature but undergoes oxidation to uric acid when exposed to xanthine oxidase.

Biological Role

Biosynthesis and Endogenous Sources

Xanthine is produced endogenously through both de novo purine biosynthesis and salvage pathways in various organisms, serving as a key intermediate in purine metabolism. In the de novo pathway, xanthine arises primarily as part of the guanine nucleotide synthesis branch from inosine monophosphate (IMP). IMP is oxidized to xanthosine monophosphate (XMP) by inosine-5'-monophosphate dehydrogenase, followed by amination to guanosine monophosphate (GMP); subsequent dephosphorylation and potential hydrolysis can yield free xanthine, though this is a minor route in humans and more prominent in microbial and plant systems where it supports alkaloid production. In humans, the guanine nucleotide cycle contributes modestly to xanthine formation, recycling GMP back through XMP intermediates during purine turnover. The salvage pathway recycles bases to regenerate , indirectly generating xanthine through enzymatic conversions. is deaminated to xanthine by deaminase (GDA, also known as cypin), a cytosolic that hydrolyzes to xanthine and , playing a central role in purine catabolic commitment steps. Hypoxanthine, derived from via purine nucleoside (PNP), is oxidized to xanthine by xanthine oxidoreductase (XOR), which exists in and forms. In humans, (HGPRT) facilitates reutilization by converting hypoxanthine to using (PRPP) as a co-substrate; xanthine phosphoribosyltransferase, which would convert xanthine to XMP, is not significant in humans but occurs in some microorganisms and parasites. Disruptions in HGPRT, as seen in Lesch-Nyhan syndrome, lead to accumulation of hypoxanthine, which is then converted to xanthine, elevating free xanthine levels. In plants, such as those producing , salvage pathways channel xanthine precursors like xanthosine toward biosynthesis, with N-methyltransferases acting on xanthine derivatives. Endogenous xanthine is present in various tissues, including the liver, , and , where XOR activity is highest, reflecting its role in local turnover. It circulates in plasma at typical concentrations of 0.5–1 μM (approximately 0.08–0.15 mg/L), derived from cellular breakdown. Dietary s from foods like are metabolized to hypoxanthine and , which contribute indirectly to xanthine pools via hepatic salvage and processes.

Metabolism and Catabolism

In biological systems, the primary catabolic pathway for xanthine occurs as the terminal step in degradation, where xanthine is oxidized to by the xanthine oxidoreductase (XOR). XOR exists in two interconvertible forms: xanthine dehydrogenase (XDH), which transfers electrons to NAD⁺, and xanthine oxidase (XO), which reduces O₂ to produce or . The preceding step involves the oxidation of hypoxanthine to xanthine, also catalyzed by XOR, generating (ROS) in the XO form or reducing NAD⁺ in the XDH form. The exhibits Michaelis-Menten kinetics with Km values typically ranging from 6 to 11 μM for both hypoxanthine and xanthine substrates under physiological conditions. Species differences in xanthine catabolism arise from the presence or absence of uricase (urate oxidase), which further metabolizes uric acid to allantoin. Humans and higher primates lack functional uricase due to gene inactivation, resulting in uric acid accumulation as the end product of purine catabolism. In contrast, rodents and most other mammals possess active uricase, enabling efficient conversion of uric acid to the more soluble allantoin for excretion. XOR activity is tightly regulated by environmental and cellular factors, including the state, which influences the reversible conversion between XDH and XO forms, with oxidative conditions favoring the ROS-producing XO. Cytokines such as interferon-γ and tumor factor-α upregulate XOR expression during , while hypoxia stabilizes hypoxia-inducible factors that enhance XOR transcription, amplifying ROS generation. This ROS production by XO plays a key role in responses but can contribute to tissue damage if dysregulated. Uric acid, the end product in humans, is primarily excreted by the kidneys through glomerular and tubular secretion, with approximately 70% reabsorbed under normal conditions. In XOR deficiencies, such as hereditary xanthinuria type I, xanthine accumulates and is excreted in elevated urinary levels (often >100 mg/day), accompanied by due to impaired formation.

Production and Uses

Industrial Production

Xanthine was first isolated in 1817 from urinary calculi, marking the beginning of its recognition as a distinct compound, though initial production relied on extraction from natural sources like animal tissues or deposits. Synthetic routes emerged in the late through the work of , who developed methods involving cyclization to produce xanthine and related compounds, establishing foundational chemical pathways for purine synthesis. The predominant industrial method remains the Traube synthesis, introduced in , which starts with the condensation of or N-substituted urea derivatives with or derivatives to form 5,6-diaminouracils, followed by imidazole ring closure using , orthoesters, or . This approach is versatile for substituted xanthines and has been adapted for commercial production of pharmaceutical precursors. One-pot variations, developed in recent decades, streamline the process by combining and cyclization steps, reducing reaction times and solvent use while maintaining efficiency. Industrial processes using Traube's method typically achieve yields of 70-90% and purities exceeding 95% after recrystallization or purification, with common byproducts including unreacted intermediates and minor analogs like derivatives. Production occurs primarily on to pilot scales due to xanthine's niche role as a starting material for drugs such as and , rather than high-volume demand. Emerging biotechnological approaches as of 2025 leverage recombinant enzymes for sustainable synthesis, including deaminase expressed in to convert to xanthine via hydrolytic , offering higher specificity and reduced chemical waste compared to traditional routes. Engineered bacterial strains, such as modified , have been explored for fermentation-based production through salvage pathways, though these remain in early development for scalability.

Pharmacological Derivatives and Applications

Xanthine derivatives, particularly methylxanthines, have been widely utilized in due to their structural modifications that enhance therapeutic efficacy. Key examples include , known chemically as 1,3,7-trimethylxanthine, which is derived from the addition of methyl groups to the xanthine core; (1,3-dimethylxanthine); and (3,7-dimethylxanthine). These compounds occur naturally in beverages like , , and cocoa. Non-methylated derivatives, such as (1-(5-oxohexyl)-3,7-dimethylxanthine), represent synthetic modifications aimed at specific vascular effects. The primary mechanisms of action for these derivatives involve of enzymes, leading to increased intracellular (cAMP) levels and subsequent relaxation. Additionally, they act as competitive antagonists at receptors (A1 and A2 subtypes), which modulates neurotransmitter release and contributes to stimulation. Methylxanthines also exhibit mild effects through enhanced renal blood flow and sodium excretion, though this is secondary to their primary actions. Therapeutically, theophylline serves as a for and (COPD) by relaxing bronchial and reducing . Caffeine functions primarily as a central nervous system stimulant, promoting alertness and countering fatigue in conditions like disorders. Pentoxifylline improves in peripheral by decreasing blood and inhibiting platelet aggregation. Pharmacokinetically, methylxanthines demonstrate high oral exceeding 90%, with rapid absorption from the . Their elimination half-lives vary from 3 to 10 hours depending on the specific derivative and individual factors, such as age and status. Metabolism occurs predominantly via the enzyme in the liver, producing active metabolites like from . Recent developments as of 2025 include novel inhibitors derived from scaffolds, designed for treatment with improved selectivity and reduced off-target effects on other enzymes. These derivatives enhance reduction while minimizing cardiovascular risks associated with earlier agents.

Clinical Significance

Toxicity and Safety Profile

Xanthine itself exhibits low in animal studies. In contrast, its methylated derivatives, such as and , demonstrate higher toxicity; for example, the oral LD50 for in rats is approximately 367 mg/kg, while for it is around 272 mg/kg. These differences highlight the enhanced potency and potential risks associated with pharmacological derivatives compared to the parent compound. Chronic exposure to elevated xanthine levels, often resulting from genetic deficiencies like deficiency, can lead to xanthinuria, characterized by hyperexcretion of xanthine in due to its poor solubility (approximately 7-10 mg/100 mL at 37°C). This condition predisposes individuals to nephrolithiasis, or kidney stone formation, which may cause recurrent urinary tract obstructions and, in severe cases, renal impairment. Management typically involves hydration and dietary restriction to mitigate stone recurrence. Overdose of xanthine derivatives like and commonly manifests as cardiovascular and neurological effects, including , , and seizures, particularly when plasma concentrations exceed therapeutic thresholds. Theophylline has a notably narrow , with optimal plasma levels maintained between 5-15 μg/mL for bronchodilation; levels above 20 μg/mL significantly increase the risk of severe toxicity, such as ventricular arrhythmias and . Caffeine overdose similarly presents with agitation and dysrhythmias, though its broader index allows higher tolerable doses in most adults. Pharmacokinetic interactions involving xanthine derivatives primarily occur via inhibition of , the main enzyme responsible for their metabolism, leading to elevated plasma levels when co-administered with inhibitors like or . Additionally, is contraindicated in patients with due to its potential to precipitate acute attacks by inducing hepatic enzymes. Rare reactions to xanthines, including and , have been reported but occur infrequently, affecting less than 1% of users. As of 2025, regulatory guidelines from the FDA and EMA emphasize safe intake limits for , a common xanthine derivative, recommending no more than 400 mg per day for healthy adults to avoid adverse effects like and cardiovascular strain; pregnant individuals should limit intake to 200 mg daily. These thresholds underscore the importance of monitoring consumption from multiple sources, such as , , and energy drinks.

Pathology and Disease Associations

Xanthinuria, a rare inherited disorder of , manifests in two primary types due to disruptions in xanthine metabolism. Type I xanthinuria results from a deficiency in xanthine (XDH), an autosomal recessive condition caused by mutations in the XDH located on 2p23.1, leading to impaired conversion of xanthine to and consequent accumulation of xanthine in urine and plasma. This deficiency often presents with xanthine urolithiasis, where insoluble xanthine crystals form kidney stones, potentially causing , , and if recurrent. In contrast, type II xanthinuria arises from a broader defect in the molybdenum cofactor biosynthesis pathway, affecting multiple enzymes including XDH and aldehyde oxidase, and is associated with severe neurological symptoms such as intractable seizures, developmental delay, and progressive due to sulfite toxicity and disrupted . Xanthine metabolism also plays an indirect role in and , conditions characterized by overproduction and deposition. In these disorders, excessive substrate availability for xanthine oxidoreductase (XOR) drives the conversion of xanthine to , exacerbating ; however, therapeutic inhibition of XOR by reduces this conversion, lowering levels and preventing flares by accumulating xanthine, which is more soluble than . Beyond these, elevated xanthine levels contribute to in cardiovascular diseases and ischemia-reperfusion injury, where XOR generates (ROS) during xanthine oxidation, promoting , , and myocardial damage post-reperfusion. Similarly, in Lesch-Nyhan syndrome, a salvage disorder due to HPRT deficiency, xanthine accumulation occurs alongside overproduction, increasing the risk of xanthine nephrolithiasis, particularly in patients treated with . Diagnosis of xanthine-related pathologies relies on elevated urinary xanthine excretion, typically exceeding 100 mg per day in affected individuals, alongside low uric acid levels and detection of xanthine crystals in stones via infrared spectroscopy. Genetic testing confirms XDH mutations for type I or molybdenum cofactor pathway defects for type II, with plasma XOR activity assays further distinguishing the subtypes. As of November 2025, research on XOR inhibitors like febuxostat continues to explore their role in mitigating ROS-mediated pathology in heart failure and neurodegeneration. Ongoing clinical trials, such as those evaluating febuxostat for oxidative stress in heart failure (e.g., reduced ventricular remodeling in phase II studies), and preclinical models linking xanthine-derived ROS to Alzheimer's disease neuronal damage, indicate potential benefits in reducing inflammation, though larger trials are needed.

Abiotic and Extraterrestrial Aspects

Prebiotic Formation

Xanthine formation in prebiotic conditions has been explored through pathways involving the polymerization of , a compound likely present in early Earth environments due to its synthesis from (HCN) and water. Under thermal or photochemical activation, formamide undergoes free radical reactions leading to xanthine and other purines, with proposed mechanisms including the formation of aminomaleononitrile intermediates that cyclize and oxidize. These processes are self-catalytic, where initial products accelerate further synthesis, and have been demonstrated in laboratory settings mimicking surface or atmospheric conditions. Cyclization of HCN represents another key prebiotic route, particularly in hydrothermal vents where elevated temperatures (up to 100–200°C) and pressures promote oligomerization into scaffolds, including xanthine. In matrices, such as those on or in interstellar analogs, HCN trapped in frozen undergoes UV-driven reactions to yield xanthine at detectable levels, with the providing a concentrated microenvironment for sequential additions of units. These vent and scenarios highlight xanthine's abiotic accessibility without enzymatic involvement. Experimental simulations, including Miller-Urey-type setups with electric discharges or UV irradiation of reducing atmospheres (e.g., CH₄, NH₃, H₂O, H₂), generate purines like xanthine alongside , though at low yields typically below 1% based on starting gas concentrations. UV irradiation plays a crucial role in driving photolysis and radical formation, while phosphates from sources stabilize intermediates and facilitate , enhancing potential incorporation into oligomers. Xanthine remains stable in acidic soups ( ~4–5), resisting under conditions akin to early oceans. As a foundational , xanthine holds evolutionary significance in the hypothesis, serving as a precursor that could evolve into canonical bases like via or , bridging abiotic synthesis to informational polymers.

Detection in Extraterrestrial Environments

Xanthine has been identified in several carbonaceous chondrites, primitive meteorites that preserve extraterrestrial organic material from the early Solar System. In the , xanthine was detected at concentrations of approximately 2.4 parts per million (ppm) using gas chromatography-mass spectrometry (GC-MS) on extracts, alongside other purines such as and hypoxanthine. Similar analyses of the Murray meteorite revealed xanthine and related purines at comparable ppm levels, confirming their extraterrestrial origin through isotopic ratios distinct from terrestrial contaminants. These findings, replicated across multiple CM2 chondrites, indicate that purine nucleobases like xanthine were synthesized abiotically in the or on parent bodies before incorporation into meteorites. In January 2025, analysis of samples from asteroid returned by NASA's mission identified nucleobases including and , indicating extraterrestrial abiotic formation of purine precursors. Observations from space missions suggest potential occurrences of xanthine or related purines in cometary and atmospheric environments. The mission to 67P/Churyumov-Gerasimenko detected a high abundance of complex organics, comprising up to 50% of the comet's dust, including nitrogen-bearing species that could serve as precursors to , though direct identification of xanthine remains elusive. Laboratory simulations of Titan's atmosphere, using plasma discharges on N₂-CH₄ mixtures to mimic , have produced tholins containing purine nucleobases, including xanthine, demonstrating plausible formation pathways under Titan-like conditions. Telescopic observations provide indirect evidence for purine formation in the (ISM). (IR) spectroscopy studies of purines embedded in analogs reveal distinct absorption bands at 1255 cm⁻¹, 940 cm⁻¹, and 878 cm⁻¹, which do not overlap with common volatiles like H₂O or CH₃OH, enabling potential detection in dense molecular clouds. These laboratory IR signatures are aiding preparations for detections with instruments like the James Webb Space Telescope's (MIRI), which has observed complex organics in protoplanetary disks. The Atacama Large Millimeter/submillimeter Array (ALMA) has observed complex organics, such as cyanoacetylene (HC₃N) and (CH₃CN), in protoplanetary disks and star-forming regions, supporting the presence of chemical networks capable of yielding purines like xanthine. These detections carry significant implications for , bolstering hypotheses of —wherein organic molecules are transported between celestial bodies via meteoroids—and abiotic origins of life. The of xanthine in meteorites demonstrates its stability against , cosmic , and excursions, as evidenced by photostability experiments on N-heterocycles showing resistance to UV irradiation in space-like conditions. Such resilience suggests purines could seed prebiotic chemistry on habitable worlds.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Xanthine
  2. http://www.chem.ucla.edu/~harding/IGOC/X/xanthine.html
  3. https://www.ncbi.nlm.nih.gov/books/NBK545245/
  4. https://pubmed.ncbi.nlm.nih.gov/36778128/
  5. https://medlineplus.gov/genetics/condition/hereditary-xanthinuria/
  6. https://www.ncbi.nlm.nih.gov/books/NBK548950/
  7. https://cdek.pharmacy.purdue.edu/mesh/D019820/
  8. https://go.drugbank.com/drugs/DB02134
  9. https://www.frontierspartnerships.org/articles/10.18388/abp.2004_3587/pdf
  10. https://sitem.herts.ac.uk/aeru/bpdb/Reports/2153.htm
  11. https://www.sigmaaldrich.com/US/en/product/sigma/x4002
  12. https://pubs.acs.org/doi/10.1021/acs.cgd.4c01717
  13. https://organicchemistrydata.org/hansreich/resources/pka/pka_data/pka-compilation-williams.pdf
  14. https://webbook.nist.gov/cgi/cbook.cgi?ID=C69896&Mask=400
  15. https://onlinelibrary.wiley.com/doi/full/10.1002/zaac.201700218
  16. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1329011/full
  17. https://www.sciencedirect.com/science/article/pii/S0092867424005208
  18. https://www.jbc.org/article/S0021-9258%2820%2976748-7/fulltext
  19. http://www.reactome.org/content/detail/R-HSA-74255.3
  20. https://pubs.rsc.org/en/content/articlelanding/2019/ra/c9ra05655f
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11089518/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10380055/
  23. https://journals.physiology.org/doi/full/10.1152/ajpregu.1999.277.6.R1697
  24. https://www.sciencedirect.com/science/article/pii/0003269782903761
  25. https://www.nature.com/articles/s41598-021-83234-9
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC11342100/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC7879036/
  28. https://www.sciencedirect.com/science/article/pii/S0925443914001501
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3757702/
  30. https://www.jci.org/articles/view/42344
  31. https://www.pnas.org/doi/10.1073/pnas.1320393111
  32. https://www.sciencedirect.com/science/article/pii/S2213231721000306
  33. https://www.nature.com/articles/ncomms7555
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4707389/
  35. https://www.sciencedirect.com/topics/medicine-and-dentistry/xanthinuria
  36. https://www.britannica.com/science/xanthine
  37. https://www.britannica.com/biography/Emil-Fischer
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC9666039/
  39. https://pubs.rsc.org/en/content/articlelanding/2017/ra/c7ra10986e
  40. https://www.sciencedirect.com/science/article/abs/pii/S0960852425010399
  41. https://www.ncbi.nlm.nih.gov/books/NBK559165/
  42. https://www.acpjournals.org/doi/10.7326/0003-4819-103-4-643_1
  43. https://www.sciencedirect.com/topics/medicine-and-dentistry/xanthine-derivative
  44. https://www.sciencedirect.com/topics/medicine-and-dentistry/methylxanthine-derivative
  45. https://emcrit.org/ibcc/caffeine/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC6273298/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC12369460/
  48. https://www.sciencedirect.com/science/article/abs/pii/S0045206821003254
  49. https://www.ncbi.nlm.nih.gov/omim/278300
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC5413754/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC4548614/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9607355/
  53. https://pubmed.ncbi.nlm.nih.gov/8976115/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC2233605/
  55. https://pubmed.ncbi.nlm.nih.gov/27423335/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8636850/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC1664875/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC7803241/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC6043999/
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC8945357/
  61. https://www.ncbi.nlm.nih.gov/gtr/conditions/C0268118/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC8615706/
  63. https://clinicaltrials.gov/study/NCT04558581
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC12095928/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7831497/
  66. https://onlinelibrary.wiley.com/doi/10.1002/qua.26362
  67. https://psecommunity.org/wp-content/plugins/wpor/includes/file/2302/LAPSE-2023.5996-1v1.pdf
  68. https://www.nature.com/articles/s41467-019-12404-1
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC9394256/
  70. https://commons.case.edu/cgi/viewcontent.cgi?article=1309&context=facultyworks
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC12135143/
  72. https://arxiv.org/pdf/0806.2286
  73. https://adsabs.harvard.edu/pdf/2002ESASP.518...15B
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3161613/
  75. https://astrobiology.com/2025/01/lifes-building-blocks-discovered-in-samples-from-asteroid-benn.html
  76. https://www.esa.int/Science_Exploration/Space_Science/Rosetta/Rosetta_s_comet_contains_ingredients_for_life
  77. https://www.sciencedirect.com/science/article/abs/pii/S2214552418300129
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC10672069/
  79. https://www.almaobservatory.org/en/press-releases/alma-reveals-carbon-rich-organic-birth-environments-of-planets/
  80. https://scholarlypublications.universiteitleiden.nl/access/item%253A3137525/view
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.